KAKKIS EMIL D (President & CEO) sold 0.4% of their position (8.27K shares) of ULTRAGENYX PHARMACEUTICAL INC. on the open market
Open‑market sale worth $413.6K — a minor trim. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 12/11/2024ACC: 0000950170-24-135521
DirectorOfficer· President & CEO
Since Mar 2026
-28.27K
Net shares
Net seller
$413.6K
Total sold
1
Open market trades
0B · 1S
2
Total transactions
28.27K disposed
Non-Derivative Transactions2
Common Stock
Indirect
Shares
−20K
Price / share
—
Trade value
—
% of position
0.9%
12/9/2024
2.22M→2.20M
Common Stock
Indirect
Shares
−8.27K
Price / share
$50.00
Trade value
$413.65K
% of position
0.4%
12/10/2024
2.20M→2.20M
Total
Net shares
−28.27K
Net value
-$413.65K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Indirect | 12/9/2024 | G · Gift | −20K | — | — | 0.9% | 2.22M | 2.20M |
| Common Stock Indirect | 12/10/2024 | S · Sale | −8.27K | $50.00 | $413.65K | 0.4% | 2.20M | 2.20M |
| Total | −28.27K | -$413.65K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
DirectShares owned564.61K
Total
564.61K direct564.61K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 564.61K | Direct |
| Total | 564.61K | 564.61K direct |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported